2022年9月22日 · The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators.

2024年11月21日 · The 2024 ELN Less-Intensive genetic risk classification is applicable to patients receiving HMA monotherapy, HMA/VEN, or AZA/IVO (for IDH1 mut AML). For patients with favorable-risk disease, the median OS times have been reported to be >24 months.

2022年9月22日 · The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the …

2022年9月8日 · These updated ELN 2022 recommendations regarding the diagnosis and classification of AML reflect the recent advancements in our understanding of AML, including the cytogenetic and mutational profiles involved.

2023年2月7日 · 2022年ELN AML指南主要就AML诊断与危险度分层、疗效标准以及治疗推荐进行了更新，哈尔滨血液病肿瘤研究所马军教授对此进行了整理和解读。 马军 教授. 1979 年赴日本东京大学医学部留学，一直致力于血液系统的良恶性疾病的诊疗，特别以治疗白血病和淋巴瘤享誉业内。 1982年在国内首先建立体外多能造血祖细胞培养体系，填补国内空白。 自1983年至今应用维甲酸和三氧化二砷序贯疗法治疗急性早幼粒细胞白血病1200余例，10年无病生存率85%，达 …

2022年eln aml指南中，分型诊断采用aml国际共识分类标准（icc） ，对aml原始细胞的诊断阈值以及新的基因突变诊断意义进行了明确。强调在定义aml分类时优先考虑基因突变。

2017年1月26日 · The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of th …

2025年3月21日 · Acute myeloid leukemia (AML) ... According to the latest European LeukemiaNet AML risk classification guidelines (ELN 2022) , updated in 2022, allo-HCT should be considered when the relapse risk ...

2024年11月21日 · Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

2022年9月22日 · The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators.